Acta Stereologica

0351-580X

 

ya que 05 diciembre 2013 :
Vista(s): 279 (1 ULiège)
Descargar(s): 99 (1 ULiège)
print        
Lorenzo Leoncini, Tiziana Megha, Stefano Lazzi, Cristiana Bellan, Rosella Vatti, Pietro Luzi, Piero Tosi, Gabriele Cevenini, Paolo Barbini, Stefano Ascani, Aspasia Briskomatis, Stefano Pileri, Rainer Kraft, Jean Laissue & Hans Cottier

Anaplastic large cell lymphomas and Hodgkin's disease: distinctive growth features and expression of p34cdc2 /cyclin B-1

Article
Open Access

Documento adjunto(s)

Anexidades

Abstract

The clinical aggressiveness of a neoplastic process is largely determined by its growth, which results from cell production minus cell loss. We evaluated the potential of growth- related parameters in the differential diagnosis of Hodgkin's disease (HD), anaplastic large cell lymphoma, common type (ALCL-C), and its Hodgkin's like variant (ALCL-HL). These three conditions share some common properties, e.g. CD30 positivity. Highly significant differences were found between HD and ALCL-C. In particular, CD30+ cells in HD exhibited markedly higher mitotic indices (MI), multinucleation indices (MNI), DNA fragmentation indices (DFI, comparable to apoptotic indices) and percentages of mummified elements (MF), but distinctly lower ana-telophase indices (ATI, index of supposedly successful mitoses) than those in ALCL-C. Interestingly, the percentages of Ki-67 (MIB-1)+ large atypical cells (LAC), often referred to as " growth fractions", did not differ significantly among the three lymphomas types tested. In view of the disturbed mitotic process of CD30 cells in HD, special attention was paid to the two major proteins regulating the G2-M phases of the cell cycle: distinctly lower percentages of LAC expressing cyclin B-l (shortly: cyclin-B) in cytoplasm and nucleus (BCN) were registered in HD than in ALCL-C, while the reverse was true for the presence of p34cdc2 (shortly, p34). As regards the above parameters, ALCL-HL took a somewhat intermediate position between HD an ALCL-C, but was closer to the latter. A stepwise discriminant analysis revealed the following order of discriminant power of the parameters used to differentiate between the lymphomas: BCN > MNI > p34 > ATI > MF > MI. The other parameters tested, including the percentages of Ki 67+ CD30+ cells, were of little or no importance in this respect. Thus, anti-cyclin-B and anti-p34 antibodies may be useful tools in an immunohistochemical distinction of HD and ALCL.

Keywords : anaplastic large cell lymphoma, cyclin B-l, growth, Hodgkin's disease, malignant lymphomas, p34

Para citar este artículo

Lorenzo Leoncini, Tiziana Megha, Stefano Lazzi, Cristiana Bellan, Rosella Vatti, Pietro Luzi, Piero Tosi, Gabriele Cevenini, Paolo Barbini, Stefano Ascani, Aspasia Briskomatis, Stefano Pileri, Rainer Kraft, Jean Laissue & Hans Cottier, «Anaplastic large cell lymphomas and Hodgkin's disease: distinctive growth features and expression of p34cdc2 /cyclin B-1», Acta Stereologica [En ligne], Volume 17 (1998), Number 1 - June 1998, 13-23 URL : https://popups.ulg.ac.be/0351-580x/index.php?id=2461.

Acerca de: Lorenzo Leoncini

Institute of Pathologic Anatomy and Histology, University of Siena, Italy

Acerca de: Tiziana Megha

Institute of Pathologic Anatomy and Histology, University of Siena, Italy

Acerca de: Stefano Lazzi

Institute of Pathologic Anatomy and Histology, University of Siena, Italy

Acerca de: Cristiana Bellan

Institute of Pathologic Anatomy and Histology, University of Siena, Italy

Acerca de: Rosella Vatti

Institute of Pathologic Anatomy and Histology, University of Siena, Italy

Acerca de: Pietro Luzi

Institute of Pathologic Anatomy and Histology, University of Siena, Italy

Acerca de: Piero Tosi

Institute of Pathologic Anatomy and Histology, University of Siena, Italy

Acerca de: Gabriele Cevenini

Institute of Thoracic and Cardiovascular Surgery and Biomedical Technology, University of Siena, Italy

Acerca de: Paolo Barbini

Institute of Thoracic and Cardiovascular Surgery and Biomedical Technology, University of Siena, Italy

Acerca de: Stefano Ascani

Institute of Hematology "L. & A. Seràgnoli", Hemolymphopathology Unit, University of Bologna, Italy

Acerca de: Aspasia Briskomatis

Institute of Hematology "L. & A. Seràgnoli", Hemolymphopathology Unit, University of Bologna, Italy

Acerca de: Stefano Pileri

Institute of Hematology "L. & A. Seràgnoli", Hemolymphopathology Unit, University of Bologna, Italy

Acerca de: Rainer Kraft

Institute of Pathology, University of Berne, Switzerland

Acerca de: Jean Laissue

Institute of Pathology, University of Berne, Switzerland

Acerca de: Hans Cottier

Institute of Pathology, University of Berne, Switzerland